Alimera Sciences (NASDAQ:ALIM) Research Coverage Started at Maxim Group

Maxim Group started coverage on shares of Alimera Sciences (NASDAQ:ALIM) in a research note released on Monday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $10.00 target price on the biopharmaceutical company’s stock.

Separately, StockNews.com started coverage on shares of Alimera Sciences in a research report on Sunday, December 31st. They set a hold rating for the company.

Alimera Sciences Price Performance

ALIM stock opened at $3.90 on Monday. The company has a fifty day moving average price of $3.77 and a 200-day moving average price of $3.55. The company has a market capitalization of $204.17 million, a P/E ratio of -1.81 and a beta of 1.16. Alimera Sciences has a 52-week low of $1.56 and a 52-week high of $4.38. The company has a debt-to-equity ratio of 1.40, a quick ratio of 2.31 and a current ratio of 2.39.

Alimera Sciences (NASDAQ:ALIM) last released its quarterly earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.09). Alimera Sciences had a negative net margin of 24.93% and a negative return on equity of 130.90%. The business had revenue of $26.31 million for the quarter, compared to the consensus estimate of $25.10 million. During the same period in the previous year, the business posted ($0.54) EPS. As a group, equities analysts expect that Alimera Sciences will post 0.03 EPS for the current year.

Institutional Investors Weigh In On Alimera Sciences

Large investors have recently bought and sold shares of the stock. Millennium Management LLC acquired a new position in shares of Alimera Sciences during the fourth quarter valued at about $32,000. Osaic Holdings Inc. acquired a new position in shares of Alimera Sciences during the second quarter valued at about $34,000. Tower Research Capital LLC TRC lifted its position in shares of Alimera Sciences by 291.8% during the third quarter. Tower Research Capital LLC TRC now owns 12,000 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 8,937 shares in the last quarter. Northern Trust Corp bought a new position in shares of Alimera Sciences during the fourth quarter valued at about $61,000. Finally, Citadel Advisors LLC bought a new position in shares of Alimera Sciences during the fourth quarter valued at about $86,000. 99.83% of the stock is currently owned by institutional investors and hedge funds.

About Alimera Sciences

Alimera Sciences, Inc, a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals. It operates through United States, internationally, and Operating Cost segments. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.